Repligen Corp. (RGEN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Tony J. Hunt
Employees:
548
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA 02453
7814499560

Repligen Corp. engages on the development, production and commercialization of products used in the process of manufacturing biological drugs. It offers upstream solutions, downstream solutions, and analytics. The upstream solutions offers XCell ATF System and cell culture supplements. The downstream solutions includes OPUS pre-packaged chromatography columns; Protein A affinity resins; and Protein A Ligands. The analytics involves ELISA kits. The company was founded by Alexander G. Rich in May 1981 and is headquartered in Waltham, MA.

Data derived from most recent annual or quarterly report
Market Cap 10.25 Billion Shares Outstanding55.289 Million Avg 30-day Volume 571.097 Thousand
P/E Ratio113.4322 Dividend Yield0.0 EPS0.61
Price to Revenue22.2921 Debt to Equity0.1556 EBITDA165.033 Million
Price to Book Value7.0712 Operating Margin24.1891 Enterprise Value10.851 Billion
Current Ratio2.96 EPS Growth2.086 Quick Ratio2.518
1 Yr BETA 1.0912 52-week High/Low 327.32 / 162.29 Profit Margin19.6523
Operating Cash Flow Growth26.355 Altman Z-Score17.4037 Free Cash Flow to Firm -228.557 Million
View SEC Filings from RGEN instead.

View recent insider trading info

Funds Holding RGEN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RGEN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KURIYEL RALF SENIOR VP, R&D

  • Officer
16,909 2021-12-14 7

HUNT ANTHONY CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
197,294 2021-11-18 7

DAWES KAREN A

  • Director
91,247 2021-11-10 10

RYAN THOMAS F JR

  • Director
40,296 2021-11-02 5

BARTHELEMY NICOLAS

  • Director
1,547 2021-10-29 2

GEBSKI CHRISTINE SEE REMARKS

  • Officer
33,318 2021-09-01 4

SNODGRES JON CHIEF FINANCIAL OFFICER

  • Officer
31,893 2021-05-14 3

MUIR GLENN P

  • Director
7,513 2021-05-13 1

EGLINTON MANNER CARRIE

  • Director
1,608 2021-05-13 1

MHATRE ROHIN

  • Director
1,608 2021-05-13 1

BYLUND JAMES SVP, GLOBAL OPERATIONS & IT

  • Officer
6,324 2021-04-06 2

COX JOHN

  • Director
923 2020-03-24 0

COOPER GLENN L MD

  • Director
35,709 2019-05-23 0

EDDLEMAN ROY T

  • 10% Owner
No longer subject to file 2018-08-09 0

BENJAMIN HOWARD VP BUSINESS DEVELOPMENT

  • Officer
33,908 2017-12-14 0

RUSCHE JAMES R SENIOR VICE PRESIDENT

  • Officer
No longer subject to file 2016-12-31 0

GOLDBERG ALFRED LEWIS

  • Director
40,331 2015-05-21 0

HERLIHY WALTER C PRESIDENT, CEO

  • Officer
  • Director
262,430 2015-05-12 0

GRIFFITH MICHAEL A

  • Director
1,932 2014-11-10 0

WITT DANIEL P SENIOR VICE PRESIDENT

  • Officer
77,999 2014-06-20 0

KELLY WILLIAM J CHIEF ACCOUNTING OFFICER

  • Officer
5,456 2014-02-27 0

HENRY EARL WEBB

  • Director
21,380 2013-05-09 0

LIEBER JONATHAN I CFO

  • Officer
15,000 2013-02-28 0

SPURR ROBERT CHIEF COMMERCIAL. OFFICER

  • Officer
10,000 2012-03-12 0

HALL MICHAEL CHIEF MEDICAL OFFICER

  • Officer
5,000 2012-03-12 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

LAMPERT MARK N

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2009-07-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KURIYEL RALF - Officer SENIOR VP, R&D

2021-12-15 21:30:18 -0500 2021-12-14 F 445 $252.53 d 16,909 direct 3.3326 3.0328 4.9988 3 0.0 1

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
REPLIGEN CORP RGEN 2022-01-26 22:15:03 UTC -0.1925 0.2625 1100000
REPLIGEN CORP RGEN 2022-01-26 21:45:03 UTC -0.1925 0.2625 1100000
REPLIGEN CORP RGEN 2022-01-26 21:15:03 UTC -0.1925 0.2625 1100000
REPLIGEN CORP RGEN 2022-01-26 20:45:04 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 20:15:03 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 19:45:03 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 19:15:04 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 18:45:03 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 18:15:04 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 17:45:03 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 17:15:03 UTC -0.1962 0.2662 1100000
REPLIGEN CORP RGEN 2022-01-26 16:45:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 16:15:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 15:45:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 15:15:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 14:45:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 14:15:04 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 13:45:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 13:15:03 UTC -0.18 0.25 1100000
REPLIGEN CORP RGEN 2022-01-26 12:45:04 UTC -0.18 0.25 1100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund RGEN -20.0 shares, $-2950.8 2020-09-30 N-PORT
Jackson Variable Series Trust- JNL/Nicholas Convertible Arbitrage Fund RGEN -12255.0 shares, $-1183097.7 2020-03-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund RGEN -1191.0 shares, $-238200.0 2021-01-31 N-PORT
Nuveen Investment Trust- Nuveen Equity Market Neutral Fund RGEN -1000.0 shares, $-182610.0 2021-05-31 N-PORT
SCHWAB CAPITAL TRUST- Schwab Hedged Equity Fund RGEN -843.0 shares, $-207125.1 2021-07-31 N-PORT
Nuveen Investment Trust II- Nuveen Equity Long/Short Fund RGEN -1500.0 shares, $-424470.0 2021-08-31 N-PORT
AGF Investments Trust- AGFIQ U.S. Market Neutral Anti-Beta Fund RGEN -1624.0 shares, $-469319.76 2021-09-30 N-PORT
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund RGEN -958.0 shares, $-276852.42 2021-09-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund RGEN -100.0 shares, $-28899.0 2021-09-30 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund RGEN -5861.0 shares, $-1702620.5 2021-10-31 N-PORT
RUSSELL INVESTMENT CO- Sustainable Equity Fund RGEN -598.0 shares, $-173719.0 2021-10-31 N-PORT
ADVISORS' INNER CIRCLE III- Knights of Columbus Long/Short Equity Fund RGEN -785.0 shares, $-228042.5 2021-10-31 N-PORT

Elevate your investments